Skip to content
NewsBlazeIN – Lifestyle
Author:
Atavistik Bio, Inc.
Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic Telangiectasia
July 30, 2026
Atavistik Bio Appoints Habib Dable to its Board of Directors
July 29, 2026
Atavistik Bio Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ATV-1601 for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
June 9, 2026